.

.

Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will.

Print Article. .

.

.

Order Reprints. Sabatolimab : Novartis; Drug profiles in the detailed report. .

Selected.

. . May 19, 2023 · May 19, 2023 12:04 pm ET.

. .

.

.

. 1 day ago · Contact Data CONTACT: ResearchAndMarkets.

Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis Mar 28, 2023 Novartis. Print Article.

May 17, 2023 · Novartis , also in the race, said last month that no signs of liver damage had been seen in trials testing its anti-inflammatory drug candidate remibrutinib so far.
.
.

Mid Stage Products (Phase II).

.

add_box. . .

Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will. Dec 23, 2021 · The latter acquired the worldwide rights to inclisiran from its developer, Alnylam Pharmaceuticals, in February 2013 for an upfront $25 million and a potential $180 million as certain development milestones passed plus double-digit royalties from sales of the ready-to-use drug. S. Print Article. . .

.

. .

.

.

.

May 22, 2023 · Why consider Novartis? 766 million lives were touched by Novartis medicines in 2021, and while we’re proud of this, we know there is so much more we could do to help improve and extend people’s lives.

.